[{"orgOrder":0,"company":"Premier","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston Scientific \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Inapplicable"},{"orgOrder":0,"company":"TIMI Study Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"TIMI Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"TIMI Study Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"TIMI Study Group \/ Inapplicable"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"University of Manitoba \/ Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI","highestDevelopmentStatusID":"10","companyTruncated":"University of Manitoba \/ Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"||Transferrin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Blau Farmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Blau Farmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ ARC Dialysis, LLC"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Suntrust Robinson Humphrey","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Suntrust Robinson Humphrey","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Suntrust Robinson Humphrey"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"Undisclosed","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ CorMedix"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Frederick Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Frederick Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Frederick Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Frederick Health \/ Inapplicable"},{"orgOrder":0,"company":"Frederick Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Frederick Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Frederick Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Frederick Health \/ Inapplicable"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"National PERT Consortium, Inc. | University Medical Center Mainz","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"ZonMw | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Leiden University Medical Center | St. Antonius Hospital | Academisch Medisch Centrum - Universiteit van Amsterdam | Isala | OLVG | Radboud U","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ ZonMw | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Leiden University Medical Center | St. Antonius Hospital | Academisch Medisch Centrum - Universiteit van Amsterdam | Isala | OLVG | Radboud U","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ ZonMw | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Leiden University Medical Center | St. Antonius Hospital | Academisch Medisch Centrum - Universiteit van Amsterdam | Isala | OLVG | Radboud U"},{"orgOrder":0,"company":"Tabba Heart Institute","sponsor":"InnoTherapy Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tabba Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Tabba Heart Institute \/ InnoTherapy Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tabba Heart Institute \/ InnoTherapy Inc"},{"orgOrder":0,"company":"Australian National University","sponsor":"Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Australian National University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Australian National University \/ Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia","highestDevelopmentStatusID":"9","companyTruncated":"Australian National University \/ Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia"},{"orgOrder":0,"company":"Fundaci\u00f3n HM","sponsor":"Syntax for Science, S.L","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fundaci\u00f3n HM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n HM \/ Syntax for Science, S.L","highestDevelopmentStatusID":"8","companyTruncated":"Fundaci\u00f3n HM \/ Syntax for Science, S.L"},{"orgOrder":0,"company":"Sydney Local Health District","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bivalirudin","moa":"||Thrombin","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sydney Local Health District \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sydney Local Health District \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Vaneltix Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||NaV channel-alpha-subunit","graph1":"Urology","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Pre-Filled Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Pharmaceuticals \/ Vaneltix Pharma"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"||NaV channel-alpha-subunit","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Pre-Filled Injection","sponsorNew":"Vaneltix Pharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"||Tissue-type plasminogen activator","graph1":"Undisclosed","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"VarmX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Heparin","moa":"||Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Inapplicable"},{"orgOrder":0,"company":"Rensselaer Polytechnic Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rensselaer Polytechnic Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rensselaer Polytechnic Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rensselaer Polytechnic Institute \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus Dmcc","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"||Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratori Derivati Organici \/ Cerus Dmcc","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus Dmcc"}]
Find Clinical Drug Pipeline Developments & Deals for Heparin
Details :
Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.
Details :
Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Details :
The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.
Details :
CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.